A Chemically Defined TLR3 Agonist with Anticancer Activity
Julie Le Naour,Sylvain Thierry,Sarah Adriana Scuderi,Mathilde Boucard-Jourdin,Peng Liu,Marc Bonnin,Yuhong Pan,Clemence Perret,Liwei Zhao,Misha Mao,Chloe Renoux,Maria Perez-Lanzon,Baptiste Martin,Oliver Kepp,Guido Kroemer,Bettina Werle
DOI: https://doi.org/10.1080/2162402x.2023.2227510
2023-01-01
OncoImmunology
Abstract:Toll-like receptor 3 (TLR3) agonists such as polyinosinic:polycytidylic acid (poly(I:C)) have immunostimulatory effects that can be taken advantage of to induce anticancer immune responses in preclinical models. In addition, poly(I:C) has been introduced into clinical trials to demonstrate its efficacy as an adjuvant and to enhance the immunogenicity of locally injected tumors, thus reverting resistance to PD-L1 blockade in melanoma patients. Here, we report the pharmacokinetic, pharmacodynamic, mechanistic and toxicological profile of a novel TLR3 agonist, TL-532, a chemically synthesized double-stranded RNA that is composed by blocks of poly(I:C) and poly(A:U) (polyadenylic - polyuridylic acid). In preclinical models, we show that TL-532 is bioavailable after parenteral injection, has an acceptable toxicological profile, and stimulates the production of multiple chemokines and interleukins that constitute pharmacodynamic markers of its immunostimulatory action. When given at a high dose, TL-532 monotherapy reduced the growth of bladder cancers growing on mice. In addition, in immunodeficient mice lacking formylpeptide receptor-1 (FPR1), TL-532 was able to restore the response of orthotopic subcutaneous fibrosarcoma to immunogenic chemotherapy. Altogether, these findings may encourage further development of TL-532 as an immunotherapeutic anticancer agent.